title: Tegillarca granosa extract Haishengsu (HSS) suppresses expression of mdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumors in mice.
abstract: OBJECTIVE
  To evaluate the effect of Haishengsu (HSS), a protein extract from Tegillarca granosa, on multidrug-resistance genes mdr1, BCR/ABL and sorcin in transplanted tumors.
  
  
  METHODS
  Mice were inoculated subcutaneously with a drug resistant leukemia cell line K562/ADM. Tumor-bearing animals were divided into control, adriamycin, HSS and combination therapy (adriamycin plus HSS) groups. Flow cytometry was used to detect apoptosis of tumor cells, and RT-PCR was used to evaluate the expression of mdr1, BCR/ABL and sorcin.
  
  
  RESULTS
  The apoptosis rate in the high (71.8%), medium (72.3%) and low doses HSS group (72.4%) was higher than in control (1.2%, p<0.01), adriamycin (34.4%, p<0.05) or combination therapy group (46.4%, p<0.05). The mean optical density of mdr1, BCR/ABL and sorcin in HSS groups was lower than in control, adriamycin and combination therapy group (p<0.01). The optical density of the three genes in high HSS group was lower than in medium and low HSS group (p<0.01).
  
  
  CONCLUSIONS
  Haishengsu promotes apoptosis of drug-resistant K562/ADM tumors in mice in a dose-dependent manner. The pro-apoptotic effect of Haishengsu may be related to a reduced expression of multidrug-resistance genes mdr1, BCR/ABL and sorcin.
authors.affiliation: Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shangdong, PR China
authors.forename: G Y
authors.initials: GY
authors.lastname: Li
authors.forename: J Z
authors.initials: JZ
authors.lastname: Liu
authors.forename: B
authors.initials: B
authors.lastname: Zhang
authors.forename: M
authors.initials: M
authors.lastname: Yang
authors.forename: S G
authors.initials: SG
authors.lastname: Chen
authors.forename: M
authors.initials: M
authors.lastname: Hou
authors.forename: L X
authors.initials: LX
authors.lastname: Wang
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000418:Albumins / Q000494:pharmacology*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D017209:Apoptosis; D049872:Bivalvia / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000378:metabolism*; D053148:Caspase 3 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D020869:Gene Expression Profiling; D006801:Humans; D020014:K562 Cells; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000418:Albumins; D002135:Calcium-Binding Proteins; D004365:Drugs, Chinese Herbal; C503113:SRI protein, human; C532636:haishengsu; D004317:Doxorubicin; D016044:Fusion Proteins, bcr-abl; D053148:Caspase 3